Vaxcyte (PCVX) Competitors $30.23 -1.81 (-5.65%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$29.65 -0.58 (-1.92%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PCVX vs. TEVA, ITCI, SMMT, GMAB, RDY, MRNA, VTRS, QGEN, ASND, and ROIVShould you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Vaxcyte vs. Teva Pharmaceutical Industries Intra-Cellular Therapies Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Qiagen Ascendis Pharma A/S Roivant Sciences Vaxcyte (NASDAQ:PCVX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, community ranking, dividends, earnings, analyst recommendations, valuation and risk. Does the MarketBeat Community favor PCVX or TEVA? Teva Pharmaceutical Industries received 1280 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 78.26% of users gave Vaxcyte an outperform vote while only 67.82% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformVaxcyteOutperform Votes5478.26% Underperform Votes1521.74% Teva Pharmaceutical IndustriesOutperform Votes133467.82% Underperform Votes63332.18% Do analysts recommend PCVX or TEVA? Vaxcyte currently has a consensus price target of $136.50, indicating a potential upside of 351.54%. Teva Pharmaceutical Industries has a consensus price target of $23.43, indicating a potential upside of 72.46%. Given Vaxcyte's stronger consensus rating and higher possible upside, research analysts plainly believe Vaxcyte is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Does the media favor PCVX or TEVA? In the previous week, Teva Pharmaceutical Industries had 10 more articles in the media than Vaxcyte. MarketBeat recorded 20 mentions for Teva Pharmaceutical Industries and 10 mentions for Vaxcyte. Teva Pharmaceutical Industries' average media sentiment score of 1.13 beat Vaxcyte's score of 0.95 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 5 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Teva Pharmaceutical Industries 15 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, PCVX or TEVA? Vaxcyte has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Do insiders and institutionals have more ownership in PCVX or TEVA? 96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is PCVX or TEVA more profitable? Vaxcyte has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -23.53% -22.20% Teva Pharmaceutical Industries -9.91%42.46%6.65% Which has better earnings & valuation, PCVX or TEVA? Vaxcyte has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$402.27M-$3.80-7.96Teva Pharmaceutical Industries$16.54B0.93-$1.64B-$1.45-9.37 SummaryVaxcyte beats Teva Pharmaceutical Industries on 11 of the 18 factors compared between the two stocks. Remove Ads Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCVX vs. The Competition Export to ExcelMetricVaxcyteBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.89B$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-6.5731.0021.6617.82Price / SalesN/A441.16373.3994.61Price / CashN/A168.6838.1534.64Price / Book2.323.476.474.00Net Income-$402.27M-$72.06M$3.20B$247.23M7 Day Performance-1.85%3.17%2.86%1.45%1 Month Performance-59.35%-16.97%-8.56%-6.24%1 Year Performance-51.43%-29.07%10.58%0.60% Vaxcyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCVXVaxcyte3.2559 of 5 stars$30.23-5.6%$136.50+351.5%-51.5%$3.89BN/A-6.57160High Trading VolumeTEVATeva Pharmaceutical Industries3.0335 of 5 stars$13.91+0.8%$23.43+68.5%+2.7%$15.77B$16.54B-9.5936,800Analyst DowngradeOptions VolumePositive NewsITCIIntra-Cellular Therapies3.4828 of 5 stars$131.87flat$106.23-19.4%N/A$14.05B$680.50M-151.57560Analyst ForecastPositive NewsSMMTSummit Therapeutics2.4654 of 5 stars$17.32-0.2%$35.40+104.4%+573.6%$12.78B$700,000.00-61.85110News CoverageGMABGenmab A/S4.214 of 5 stars$18.19-1.1%$41.33+127.2%-33.9%$12.04B$21.53B10.451,660Short Interest ↓Gap DownHigh Trading VolumeRDYDr. Reddy's Laboratories3.4793 of 5 stars$12.59+1.8%$17.00+35.1%-6.3%$10.51B$311.31B20.0424,800High Trading VolumeMRNAModerna4.2561 of 5 stars$25.64+2.1%$59.00+130.1%-74.7%$9.91B$3.20B-2.763,900Gap DownVTRSViatris2.9705 of 5 stars$7.61-0.1%$10.50+38.0%-33.9%$9.08B$14.74B-10.2837,000High Trading VolumeQGENQiagen3.3616 of 5 stars$40.33+5.4%$47.71+18.3%+7.7%$8.96B$1.98B112.296,030High Trading VolumeASNDAscendis Pharma A/S2.3101 of 5 stars$140.14-1.8%$204.64+46.0%+6.0%$8.50B$363.64M-19.741,017Positive NewsGap DownROIVRoivant Sciences2.6314 of 5 stars$9.26-2.1%$17.50+89.0%-7.2%$6.61B$122.59M-61.73860Positive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Teva Pharmaceutical Industries Competitors Intra-Cellular Therapies Competitors Summit Therapeutics Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Viatris Competitors Qiagen Competitors Ascendis Pharma A/S Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCVX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PCVX Stock Free PCVX Stock Alerts